Mahsa Akbari Oryani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Mahsa Akbari Oryani has a total of 59 co-authors. Here are the top co-authors by number of shared publications:
- Alireza Hashemzadeh
Department of Clinical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
4 shared publications - Mojtaba Tarin
Department of Chemistry, Faculty of Science, Ferdowsi University of Mashhad, Mashhad, Iran
4 shared publications - Hossein Javid
Varastegan Institute for Medical Sciences
3 shared publications - Mehdi Karimi-Shahri
Department of Pathology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
3 shared publications - Zahra Payandeh
Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
3 shared publications - Ali Azargoonjahromi
Shiraz University of Medical Sciences, Shiraz, Iran
2 shared publications
Latest Publications
- 24 September 2026
- Published by Bentham Science Publishers Ltd. in Anti-Cancer Agents in Medicinal Chemistry
- Vol. 26, 1-18
Synergistic Fusion: Enhancing Cancer Treatment with Herbal-Chemotherapy Nanocomplexes
Introduction: The ongoing battle against cancer highlights the limitations of conventional treatments, underscoring the pressing need for therapies that mitigate systemic toxicity and multidrug resistance (MDR). Co-administering herbal medications with chemotherapeutics via nanodelivery systems offers a promising approach to addressing these oncology challenges. Methods: A narrative review was conducted using PubMed, Scopus, and Web of Science to identify relevant literature published between 2010 and 2026. Search terms included "herbal medicine," "chemotherapy," "nanoparticles," and "co-delivery" using standard Boolean operators (AND, OR). A total of 845 studies were initially screened, from which 137 were selected based on strict inclusion and exclusion criteria. Studies were critically selected based on their evaluation of in vivo efficacy, nanocarrier design, and mechanisms of synergy. Results: Phytochemicals such as curcumin, ginsenosides, and quercetin exhibit significant synergistic potential when combined with agents like doxorubicin and paclitaxel. Critical analysis reveals that while nanocarriers (e.g., liposomes, polymeric nanoparticles) improve bioavailability and selectively target tumors via the enhanced permeability and retention (EPR) effect, comparative metrics like loading efficiency and in vivo toxicity vary widely. The current data remain predominantly preclinical. Discussion: Despite promising pharmacodynamics, clinical translation is hindered by formulation instability, a lack of standardized herbal extracts, and complex pharmacokinetic interactions, including cytochrome P450 (CYP450) modulation. Conclusion: The combination of herbal medicines and chemotherapeutic agents via nanocarriers establishes a promising framework for cancer treatment. However, realizing their potential requires rigorous clinical validation, standardized pharmacokinetic modeling, and scalable manufacturing protocols to move beyond preclinical limitations.
- 24 September 2026
- Published by Bentham Science Publishers Ltd. in Anti-Cancer Agents in Medicinal Chemistry
- Vol. 26, 1-18
Synergistic Fusion: Enhancing Cancer Treatment with Herbal-Chemotherapy Nanocomplexes
Introduction: The ongoing battle against cancer highlights the limitations of conventional treatments, underscoring the pressing need for therapies that mitigate systemic toxicity and multidrug resistance (MDR). Co-administering herbal medications with chemotherapeutics via nanodelivery systems offers a promising approach to addressing these oncology challenges. Methods: A narrative review was conducted using PubMed, Scopus, and Web of Science to identify relevant literature published between 2010 and 2026. Search terms included "herbal medicine," "chemotherapy," "nanoparticles," and "co-delivery" using standard Boolean operators (AND, OR). A total of 845 studies were initially screened, from which 137 were selected based on strict inclusion and exclusion criteria. Studies were critically selected based on their evaluation of in vivo efficacy, nanocarrier design, and mechanisms of synergy. Results: Phytochemicals such as curcumin, ginsenosides, and quercetin exhibit significant synergistic potential when combined with agents like doxorubicin and paclitaxel. Critical analysis reveals that while nanocarriers (e.g., liposomes, polymeric nanoparticles) improve bioavailability and selectively target tumors via the enhanced permeability and retention (EPR) effect, comparative metrics like loading efficiency and in vivo toxicity vary widely. The current data remain predominantly preclinical. Discussion: Despite promising pharmacodynamics, clinical translation is hindered by formulation instability, a lack of standardized herbal extracts, and complex pharmacokinetic interactions, including cytochrome P450 (CYP450) modulation. Conclusion: The combination of herbal medicines and chemotherapeutic agents via nanocarriers establishes a promising framework for cancer treatment. However, realizing their potential requires rigorous clinical validation, standardized pharmacokinetic modeling, and scalable manufacturing protocols to move beyond preclinical limitations.
- Open Access
- 1 August 2026
- Published by Brieflands in International Journal of Cancer Management
- Vol. 19 (1) , e168427
Association Between Computed Tomography Characteristics and Ultrasound-Based Risk Stratification in Incidental Thyroid Nodules of Oncologic Patients
Background: Incidental thyroid nodules (ITNs) are frequently detected in oncologic patients undergoing computed tomography (CT). However, the diagnostic accuracy of CT for these nodules, particularly in comparison with ultrasound-based Thyroid Imaging Reporting and Data System (TIRADS) and Korean Thyroid Imaging Reporting and Data System (K-TIRADS) classifications, remains unclear. Objectives: We evaluated the diagnostic accuracy of CT for characterizing high-risk sonographic patterns in ITNs in oncologic patients by comparing CT findings with ultrasound-based classifications. Methods: This retrospective study analyzed 420 oncologic patients who underwent contrast-enhanced chest CT. Of the 65 patients with ITNs, 55 were included in the final analysis, comprising 81 nodules. CT findings, including density, enhancement, calcification, and size, were compared with the TIRADS and K-TIRADS ultrasound classifications. Fine-needle aspiration (FNA) was performed when indicated according to the K-TIRADS criteria. Statistical analyses included the intraclass correlation coefficient (ICC), chi-squared tests, logistic regression, and receiver operating characteristic (ROC) curve analysis. Results: ROC analysis of enhancement-based prediction yielded an area under the curve of 0.86 (95% CI, 0.78 - 0.94) for K-TIRADS and 0.88 (95% CI, 0.80 - 0.94) for TIRADS. The optimal enhancement threshold for high-risk sonographic patterns was 38.8 Hounsfield units (HU). Diagnostic accuracy was 80.0% (95% CI, 69.0%-88.0%) for K-TIRADS and 78.0% (95% CI, 68.0%-87.0%) for TIRADS. Calcification was significantly associated with both TIRADS (P < 0.01) and K-TIRADS (P = 0.04). CT and ultrasound measurements of nodule size were strongly correlated (ICC = 0.96; P < 0.001). Follicular adenoma was the most common final diagnosis after FNA (63.2%). Conclusions: CT enhancement and calcification patterns provide complementary diagnostic value for ITNs in oncologic patients and may facilitate more targeted management. However, ultrasound remains essential for evaluating high-risk patterns. These findings suggest that CT may serve as a useful adjunct in ITN triage.
- 1 August 2026
- Published by Brieflands in International Journal of Cancer Management
- Vol. 19 (1) , e168427
Open AccessAssociation Between Computed Tomography Characteristics and Ultrasound-Based Risk Stratification in Incidental Thyroid Nodules of Oncologic Patients
Background: Incidental thyroid nodules (ITNs) are frequently detected in oncologic patients undergoing computed tomography (CT). However, the diagnostic accuracy of CT for these nodules, particularly in comparison with ultrasound-based Thyroid Imaging Reporting and Data System (TIRADS) and Korean Thyroid Imaging Reporting and Data System (K-TIRADS) classifications, remains unclear. Objectives: We evaluated the diagnostic accuracy of CT for characterizing high-risk sonographic patterns in ITNs in oncologic patients by comparing CT findings with ultrasound-based classifications. Methods: This retrospective study analyzed 420 oncologic patients who underwent contrast-enhanced chest CT. Of the 65 patients with ITNs, 55 were included in the final analysis, comprising 81 nodules. CT findings, including density, enhancement, calcification, and size, were compared with the TIRADS and K-TIRADS ultrasound classifications. Fine-needle aspiration (FNA) was performed when indicated according to the K-TIRADS criteria. Statistical analyses included the intraclass correlation coefficient (ICC), chi-squared tests, logistic regression, and receiver operating characteristic (ROC) curve analysis. Results: ROC analysis of enhancement-based prediction yielded an area under the curve of 0.86 (95% CI, 0.78 - 0.94) for K-TIRADS and 0.88 (95% CI, 0.80 - 0.94) for TIRADS. The optimal enhancement threshold for high-risk sonographic patterns was 38.8 Hounsfield units (HU). Diagnostic accuracy was 80.0% (95% CI, 69.0%-88.0%) for K-TIRADS and 78.0% (95% CI, 68.0%-87.0%) for TIRADS. Calcification was significantly associated with both TIRADS (P < 0.01) and K-TIRADS (P = 0.04). CT and ultrasound measurements of nodule size were strongly correlated (ICC = 0.96; P < 0.001). Follicular adenoma was the most common final diagnosis after FNA (63.2%). Conclusions: CT enhancement and calcification patterns provide complementary diagnostic value for ITNs in oncologic patients and may facilitate more targeted management. However, ultrasound remains essential for evaluating high-risk patterns. These findings suggest that CT may serve as a useful adjunct in ITN triage.
- 12 June 2026
- Published by IOP Publishing in Nanotechnology
- Vol. 37 (23) , 232005
Synergistic engineering of pH-responsive MSN@ZIF-8 core–shell nanohybrids for targeted cancer therapy: from rational design to clinical potential
This review critically examines the structural design and therapeutic mechanisms of hybrid nanocarriers combining mesoporous silica nanoparticles (MSNs) and Zeolitic imidazolate framework-8 (ZIF-8). While conventional chemotherapy is hindered by off-target toxicity and multidrug resistance, MSN@ZIF-8 hybrids offer a sophisticated solution by integrating the high cargo capacity of silica cores with the pH-gated degradability of ZIF-8 shells. Rather than a simple catalogue of recent studies, this article synthesizes the rational design logic behind solid versus hollow core architectures, elucidates the physicochemical principles of pH-triggered release, specifically the protonation of imidazole linkers, and analyzes the role of surface properties such as zeta potential, surface area, and wettability in cellular interaction. We highlight recent breakthroughs in co-delivery systems for chemotherapy, gene therapy, and theranostics, emphasizing the synergistic impact of Zn 2+ -mediated reactive oxygen species generation. Finally, we move beyond general limitations to address specific translational barriers, including batch-to-batch reproducibility, scale-up of interfacial synthesis, and long-term formulation stability, proposing a roadmap for bridging the gap between benchtop innovation and clinical reality.
- 12 June 2026
- Published by IOP Publishing in Nanotechnology
- Vol. 37 (23) , 232005
Synergistic engineering of pH-responsive MSN@ZIF-8 core–shell nanohybrids for targeted cancer therapy: from rational design to clinical potential
This review critically examines the structural design and therapeutic mechanisms of hybrid nanocarriers combining mesoporous silica nanoparticles (MSNs) and Zeolitic imidazolate framework-8 (ZIF-8). While conventional chemotherapy is hindered by off-target toxicity and multidrug resistance, MSN@ZIF-8 hybrids offer a sophisticated solution by integrating the high cargo capacity of silica cores with the pH-gated degradability of ZIF-8 shells. Rather than a simple catalogue of recent studies, this article synthesizes the rational design logic behind solid versus hollow core architectures, elucidates the physicochemical principles of pH-triggered release, specifically the protonation of imidazole linkers, and analyzes the role of surface properties such as zeta potential, surface area, and wettability in cellular interaction. We highlight recent breakthroughs in co-delivery systems for chemotherapy, gene therapy, and theranostics, emphasizing the synergistic impact of Zn 2+ -mediated reactive oxygen species generation. Finally, we move beyond general limitations to address specific translational barriers, including batch-to-batch reproducibility, scale-up of interfacial synthesis, and long-term formulation stability, proposing a roadmap for bridging the gap between benchtop innovation and clinical reality.
- Open Access
- 6 June 2026
- Published by Wiley in Clinical Case Reports
- Vol. 14 (6) , e72856
Idiopathic Granulomatous Mastitis in a Nulliparous Woman With Autism Spectrum Disorder Receiving Long‐Term Psychotropic Treatment and Normal Serum Prolactin Level: A Case Report
Idiopathic granulomatous mastitis (IGM) is a rare inflammatory breast disorder, primarily attributed to immunological dysregulation, hormonal imbalances, or fertility‐related conditions. We report a 26‐year‐old female with autism spectrum disorder (ASD) under long‐term multidrug psychotropic treatment who developed IGM. She had been treated with methylphenidate for at least 23 years and aripiprazole, clozapine, citalopram, valproate sodium, and propranolol for at least 10 years. The patient was sexually inactive, had no fertility‐related risk factors, and no prior use of contraceptive pills. She had no history of breast‐related disorders. She presented with induration and erythema of the right breast. Ultrasound examination showed multiple organized hypoechoic collections and recommended core needle biopsy (BIRADS 4a). Pathologic evaluation revealed granulomatous mastitis, and no neoplastic lesion was identified. Her prolactin level was 17.8 ng/mL (reference range: 4.7–23.3 ng/mL). She was prescribed oral antibiotics, corticosteroids, and anti‐inflammatory drugs. Due to the patient's improvement during follow‐up visits, the oral corticosteroid was tapered and antibiotic therapy was discontinued. On the last visit, 5 months and 24 days after the first visit, the breast presentation exhibited complete improvement, and corticosteroid therapy was discontinued. Although a clear relationship cannot be determined from a single case, prolonged exposure to psychotropic medications may contribute to immune dysregulation and oxidative stress, potentially associated with the development of IGM.
- 6 June 2026
- Published by Wiley in Clinical Case Reports
- Vol. 14 (6) , e72856
Open AccessIdiopathic Granulomatous Mastitis in a Nulliparous Woman With Autism Spectrum Disorder Receiving Long‐Term Psychotropic Treatment and Normal Serum Prolactin Level: A Case Report
Idiopathic granulomatous mastitis (IGM) is a rare inflammatory breast disorder, primarily attributed to immunological dysregulation, hormonal imbalances, or fertility‐related conditions. We report a 26‐year‐old female with autism spectrum disorder (ASD) under long‐term multidrug psychotropic treatment who developed IGM. She had been treated with methylphenidate for at least 23 years and aripiprazole, clozapine, citalopram, valproate sodium, and propranolol for at least 10 years. The patient was sexually inactive, had no fertility‐related risk factors, and no prior use of contraceptive pills. She had no history of breast‐related disorders. She presented with induration and erythema of the right breast. Ultrasound examination showed multiple organized hypoechoic collections and recommended core needle biopsy (BIRADS 4a). Pathologic evaluation revealed granulomatous mastitis, and no neoplastic lesion was identified. Her prolactin level was 17.8 ng/mL (reference range: 4.7–23.3 ng/mL). She was prescribed oral antibiotics, corticosteroids, and anti‐inflammatory drugs. Due to the patient's improvement during follow‐up visits, the oral corticosteroid was tapered and antibiotic therapy was discontinued. On the last visit, 5 months and 24 days after the first visit, the breast presentation exhibited complete improvement, and corticosteroid therapy was discontinued. Although a clear relationship cannot be determined from a single case, prolonged exposure to psychotropic medications may contribute to immune dysregulation and oxidative stress, potentially associated with the development of IGM.
- 27 April 2025
- Published by Elsevier in Carbohydrate Polymers
- Vol. 362, 123656
Advancements in chitosan-based nanocomposites with ZIF-8 nanoparticles: multifunctional platforms for wound healing applications
- 27 April 2025
- Published by Elsevier in Carbohydrate Polymers
- Vol. 362, 123656
Advancements in chitosan-based nanocomposites with ZIF-8 nanoparticles: multifunctional platforms for wound healing applications
- 2 December 2024
- Published by Taylor & Francis in Journal of Drug Targeting
- Vol. 33 (4) , 473-491
Synergistic cancer treatment using porphyrin-based metal-organic Frameworks for photodynamic and photothermal therapy
Recent advancements in multifunctional nanomaterials for cancer therapy have highlighted porphyrin-based metal-organic frameworks (MOFs) as promising candidates due to their unique properties and versatile applications. This overview focuses on the use of porphyrin-based MOFs for combined photodynamic therapy (PDT) and photothermal therapy (PTT) in cancer treatment. Porphyrin-based MOFs offer high porosity, tuneable structures, and excellent stability, making them ideal for drug delivery and therapeutic applications. The incorporation of porphyrin molecules into the MOF framework enhances light absorption and energy transfer, leading to improved photodynamic and photothermal effects. Additionally, the porosity of MOFs allows for the encapsulation of therapeutic agents, further enhancing efficacy. In PDT, porphyrin-based MOFs generate reactive oxygen species (ROS) upon light activation, destroying cancer cells. The photothermal properties enable the conversion of light energy into heat, resulting in localised hyperthermia and tumour ablation. The combination of PDT and PTT in a single platform offers synergistic effects, leading to better therapeutic outcomes, reduced side effects, and improved selectivity. This dual-modal treatment strategy provides precise spatiotemporal control over the treatment process, paving the way for next-generation therapeutics with enhanced efficacy and reduced side effects. Further research and optimisation are needed for clinical applications.
- 2 December 2024
- Published by Taylor & Francis in Journal of Drug Targeting
- Vol. 33 (4) , 473-491
Synergistic cancer treatment using porphyrin-based metal-organic Frameworks for photodynamic and photothermal therapy
Recent advancements in multifunctional nanomaterials for cancer therapy have highlighted porphyrin-based metal-organic frameworks (MOFs) as promising candidates due to their unique properties and versatile applications. This overview focuses on the use of porphyrin-based MOFs for combined photodynamic therapy (PDT) and photothermal therapy (PTT) in cancer treatment. Porphyrin-based MOFs offer high porosity, tuneable structures, and excellent stability, making them ideal for drug delivery and therapeutic applications. The incorporation of porphyrin molecules into the MOF framework enhances light absorption and energy transfer, leading to improved photodynamic and photothermal effects. Additionally, the porosity of MOFs allows for the encapsulation of therapeutic agents, further enhancing efficacy. In PDT, porphyrin-based MOFs generate reactive oxygen species (ROS) upon light activation, destroying cancer cells. The photothermal properties enable the conversion of light energy into heat, resulting in localised hyperthermia and tumour ablation. The combination of PDT and PTT in a single platform offers synergistic effects, leading to better therapeutic outcomes, reduced side effects, and improved selectivity. This dual-modal treatment strategy provides precise spatiotemporal control over the treatment process, paving the way for next-generation therapeutics with enhanced efficacy and reduced side effects. Further research and optimisation are needed for clinical applications.
- Open Access
- 1 July 2024
- Published by Apex Publishing in Iranian Journal of Breast Diseases
- Vol. 17 (3) , 82-94
Evaluation of sensitivity and specificity of intraoperative frozen section analysis of margins in patients with breast carcinoma during breast-conserving surgery and its importance in reducing the rate of re-operation
Introduction: Intra-operative frozen section analysis (IOFSA) during breast-conserving surgery (BCS) is recommended to reduce the need for reoperation and its complications. The present study aimed to assess the sensitivity and specificity of IOFSA to determine the margin in specimens of breast cancer lumpectomy during BCS in patients with invasive and ...
- 1 July 2024
- Published by Apex Publishing in Iranian Journal of Breast Diseases
- Vol. 17 (3) , 82-94
Open AccessEvaluation of sensitivity and specificity of intraoperative frozen section analysis of margins in patients with breast carcinoma during breast-conserving surgery and its importance in reducing the rate of re-operation
Introduction: Intra-operative frozen section analysis (IOFSA) during breast-conserving surgery (BCS) is recommended to reduce the need for reoperation and its complications. The present study aimed to assess the sensitivity and specificity of IOFSA to determine the margin in specimens of breast cancer lumpectomy during BCS in patients with invasive and ...
- Open Access
- 1 September 2023
- Published by Medknow in Indian Journal of Dermatology
- Vol. 68 (5) , 541-545
Immunohistochemical Evaluation of C4d and C3d Markers in Bullous Pemphigoid as a Substitute for Direct Immunofluorescence Technique
Background: There are several methods for the diagnosis of autoimmune bullous disease. Direct immunofluorescent (DIF) testing is an important diagnostic method in the diagnosis of immunobullous disease but requires skilled pathologist, fresh tissue and well-equipped laboratory to perform the procedure. The immunohistochemistry analysis of C4d and C3d is easily compared with other methods. This study was conducted to assess the value of immunohistochemistry (IHC) analysis for expressions of C3d and C4d in the diagnosis of bullous pemphigoid (BP). Aims and Objectives: This study was conducted to assess the value of immunohistochemistry (IHC) analysis for expressions of C3d and C4d in the diagnosis of bullous pemphigoid (BP). Materials and Method: We applied C4d and C3d immunohistochemistry on formalin-fixed, paraffin-embedded tissue on 30 cases of bullous pemphigoid that was confirmed by direct immunofluorescence (DIF) evaluation as well as 16 cases in control group (12 cases of herpetiform dermatitis, 3 cases of linear IgA dermatosis and 3 cases of bullous lichen planus). Results: Mean and SD of age were 68.13 ± 14.00, female to male ratio was 1:3. In cases where both C3d and C4d staining were positive, the intensity of C3d staining was higher than C4d. Twenty-two cases showed C4d-positive staining in IHC study, such that in seven cases focal staining and in 15 cases diffuse staining were observed. Also 26 cases showed C3d-positive staining in IHC study such that in four cases focal staining and in 22 cases diffuse staining were observed. In cases with C3d-positive staining, there were 21 cases of deposition only on the bullous floor, one case on the bullous roof and four cases on the bullous roof and floor. In cases with C4d-positive staining, there were 17 cases of deposition on the bullous floor, two cases only on the bullous roof and three cases on the roof and floor. All control cases were negative for C3d and C4d staining in the dermoepidermal junction. For C3d immunohistochemical staining, sensitivity, specificity, positive predictive value and negative predictive value were 86.66%, 100%, 100% and 80%, respectively, and for C4d immunohistochemical staining, respectively, were 73.3%, 100%, 100% and 66.66%. Conclusion: The immunohistochemical specificity of C4d and C3d on tissue blocks is the same as that of direct immunofluorescence test on fresh tissue, but it is less sensitive, so positive results for C3d and C4d immunohistochemical staining on paraffin blocks can be used to confirm the diagnosis of bullous pemphigoid.
- 1 September 2023
- Published by Medknow in Indian Journal of Dermatology
- Vol. 68 (5) , 541-545
Open AccessImmunohistochemical Evaluation of C4d and C3d Markers in Bullous Pemphigoid as a Substitute for Direct Immunofluorescence Technique
Background: There are several methods for the diagnosis of autoimmune bullous disease. Direct immunofluorescent (DIF) testing is an important diagnostic method in the diagnosis of immunobullous disease but requires skilled pathologist, fresh tissue and well-equipped laboratory to perform the procedure. The immunohistochemistry analysis of C4d and C3d is easily compared with other methods. This study was conducted to assess the value of immunohistochemistry (IHC) analysis for expressions of C3d and C4d in the diagnosis of bullous pemphigoid (BP). Aims and Objectives: This study was conducted to assess the value of immunohistochemistry (IHC) analysis for expressions of C3d and C4d in the diagnosis of bullous pemphigoid (BP). Materials and Method: We applied C4d and C3d immunohistochemistry on formalin-fixed, paraffin-embedded tissue on 30 cases of bullous pemphigoid that was confirmed by direct immunofluorescence (DIF) evaluation as well as 16 cases in control group (12 cases of herpetiform dermatitis, 3 cases of linear IgA dermatosis and 3 cases of bullous lichen planus). Results: Mean and SD of age were 68.13 ± 14.00, female to male ratio was 1:3. In cases where both C3d and C4d staining were positive, the intensity of C3d staining was higher than C4d. Twenty-two cases showed C4d-positive staining in IHC study, such that in seven cases focal staining and in 15 cases diffuse staining were observed. Also 26 cases showed C3d-positive staining in IHC study such that in four cases focal staining and in 22 cases diffuse staining were observed. In cases with C3d-positive staining, there were 21 cases of deposition only on the bullous floor, one case on the bullous roof and four cases on the bullous roof and floor. In cases with C4d-positive staining, there were 17 cases of deposition on the bullous floor, two cases only on the bullous roof and three cases on the roof and floor. All control cases were negative for C3d and C4d staining in the dermoepidermal junction. For C3d immunohistochemical staining, sensitivity, specificity, positive predictive value and negative predictive value were 86.66%, 100%, 100% and 80%, respectively, and for C4d immunohistochemical staining, respectively, were 73.3%, 100%, 100% and 66.66%. Conclusion: The immunohistochemical specificity of C4d and C3d on tissue blocks is the same as that of direct immunofluorescence test on fresh tissue, but it is less sensitive, so positive results for C3d and C4d immunohistochemical staining on paraffin blocks can be used to confirm the diagnosis of bullous pemphigoid.
- Open Access
- 5 September 2022
- Published by Springer Nature in Cellular & Molecular Biology Letters
- Vol. 27 (1) , 1-28
Exosome application in treatment and diagnosis of B-cell disorders: leukemias, multiple sclerosis, and arthritis rheumatoid
Exosomes, known as a type of extracellular vesicles (EVs), are lipid particles comprising heterogeneous contents such as nucleic acids, proteins, and DNA. These bi-layered particles are naturally released into the extracellular periphery by a variety of cells such as neoplastic cells. Given that exosomes have unique properties, they can be used as vectors and carriers of biological and medicinal particles like drugs for delivering to the desired areas. The proteins and RNAs being encompassed by the circulating exosomes in B-cell malignancies are deemed as the promising sources for diagnostic and prognostic biomarkers, as well as therapeutic agents. Exosomes can also provide a “snapshot” view of the tumor and metastatic landscape at any particular time. Further, clinical research has shown that exosomes are produced by immune cells such as dendritic cells can stimulate the immune system, so these exosomes can be used in antitumor vaccines. Despite the great potential of exosomes in the fields of diagnostic and treatment, further studies are in need for these purposes to reach a convergence notion. This review highlights the applications of exosomes in multiple immune-related diseases, including chronic lymphocytic leukemia, multiple sclerosis, and arthritis rheumatoid, as well as explaining sundry aspects of exosome therapy and the function of exosomes in diagnosing diseases.
- 5 September 2022
- Published by Springer Nature in Cellular & Molecular Biology Letters
- Vol. 27 (1) , 1-28
Open AccessExosome application in treatment and diagnosis of B-cell disorders: leukemias, multiple sclerosis, and arthritis rheumatoid
Exosomes, known as a type of extracellular vesicles (EVs), are lipid particles comprising heterogeneous contents such as nucleic acids, proteins, and DNA. These bi-layered particles are naturally released into the extracellular periphery by a variety of cells such as neoplastic cells. Given that exosomes have unique properties, they can be used as vectors and carriers of biological and medicinal particles like drugs for delivering to the desired areas. The proteins and RNAs being encompassed by the circulating exosomes in B-cell malignancies are deemed as the promising sources for diagnostic and prognostic biomarkers, as well as therapeutic agents. Exosomes can also provide a “snapshot” view of the tumor and metastatic landscape at any particular time. Further, clinical research has shown that exosomes are produced by immune cells such as dendritic cells can stimulate the immune system, so these exosomes can be used in antitumor vaccines. Despite the great potential of exosomes in the fields of diagnostic and treatment, further studies are in need for these purposes to reach a convergence notion. This review highlights the applications of exosomes in multiple immune-related diseases, including chronic lymphocytic leukemia, multiple sclerosis, and arthritis rheumatoid, as well as explaining sundry aspects of exosome therapy and the function of exosomes in diagnosing diseases.
- Open Access
- 28 June 2022
- Published by Springer Nature in Cellular & Molecular Biology Letters
- Vol. 27 (1) , 1-25
The role of epigenetic modifications in drug resistance and treatment of breast cancer
Background: Breast cancer is defined as a biological and molecular heterogeneous disorder that originates from breast cells. Genetic predisposition is the most important factor giving rise to this malignancy. The most notable mutations in breast cancer occur in the BRCA1 and BRCA2 genes. Owing to disease heterogeneity, lack of therapeutic target, anti-cancer drug resistance, residual disease, and recurrence, researchers are faced with challenges in developing strategies to treat patients with breast cancer. Results: It has recently been reported that epigenetic processes such as DNA methylation and histone modification, as well as microRNAs (miRNAs), have potently contributed to the pathophysiology, diagnosis, and treatment of breast cancer. These observations have persuaded researchers to move their therapeutic approaches beyond the genetic framework toward the epigenetic concept. Conclusion: Herein we discuss the molecular and epigenetic mechanisms underlying breast cancer progression and resistance as well as various aspects of epigenetic-based therapies as monotherapy and combined with immunotherapy.
- 28 June 2022
- Published by Springer Nature in Cellular & Molecular Biology Letters
- Vol. 27 (1) , 1-25
Open AccessThe role of epigenetic modifications in drug resistance and treatment of breast cancer
Background: Breast cancer is defined as a biological and molecular heterogeneous disorder that originates from breast cells. Genetic predisposition is the most important factor giving rise to this malignancy. The most notable mutations in breast cancer occur in the BRCA1 and BRCA2 genes. Owing to disease heterogeneity, lack of therapeutic target, anti-cancer drug resistance, residual disease, and recurrence, researchers are faced with challenges in developing strategies to treat patients with breast cancer. Results: It has recently been reported that epigenetic processes such as DNA methylation and histone modification, as well as microRNAs (miRNAs), have potently contributed to the pathophysiology, diagnosis, and treatment of breast cancer. These observations have persuaded researchers to move their therapeutic approaches beyond the genetic framework toward the epigenetic concept. Conclusion: Herein we discuss the molecular and epigenetic mechanisms underlying breast cancer progression and resistance as well as various aspects of epigenetic-based therapies as monotherapy and combined with immunotherapy.